NCT04624633 - Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

December 21, 2023

Study Completion Date

January 1, 2028

Conditions

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaRelapsed Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia

Interventions

DRUG

Acalabrutinib

Oral, twice a day, predetermined dosage

DRUG

Umbralisib

Oral, once a day, predetermined dosage, each 28 day cycle up to 24 cycles

DRUG

Ublituximab

28 day cycle, starting cycle 7 via iv, on at predetermined dosage and timepoints in each cycle

Trial Locations (1)

Dana Farber Cancer Institute, Boston